Abstract
To determine the prognostic value of the timing of circulating breast tumour cell measurement during treatment, peripheral blood from 164 patients with breast disease was collected. Circulating tumour cells (CTCs) were enriched by using immunomagnetic nanospheres (IMNs) and were identified by using immunofluorescent staining. The CTC shows nuclear-positive, EpCAM-positive, CK19-positive, and CD45-negative. Patients with CTC positivity (> 19/7.5 mL blood) had shorter progression-free survival (PFS) and overall survival (OS) than those with negative results (≤ 19/7.5 mL blood) at baseline. Surgery caused an increase in the number and prevalence of CTCs, and the effect disappeared on day 14 after surgery. During adjuvant chemotherapy, CTCs detected before therapy was only correlated with PFS; however, CTCs at the end of adjuvant chemotherapy were correlated with both PFS and OS. The PFS and OS of the CTC-positive group were significantly shorter than those of the CTC-negative group at the end-point follow-up visit. The prognostic value of CTCs at different measurement time points was demonstrated during breast cancer treatment. Surgery and chemotherapy affected the prevalence of CTCs, leading to different prognostic relevance of CTCs at different treatment stages. CTCs detected at baseline or in the late phase of treatment are preferable for prognosis.
Highlights
To determine the prognostic value of the timing of circulating breast tumour cell measurement during treatment, peripheral blood from 164 patients with breast disease was collected
Many prospective studies including large-scale multi-centre research confirmed that the number of Circulating tumour cells (CTCs) over 5/7.5 ml blood detected by CellSearch system in metastatic breast cancer was associated with poor Âprognosis[7,10,11,12]
One study showed that progression-free survival (PFS) and overall survival (OS) were significantly associated with the number of CTCs after adjuvant chemotherapy but not at 1-week post-surgery[18], indicating that the measurement time point could affect the prognostic value of CTCs
Summary
To determine the prognostic value of the timing of circulating breast tumour cell measurement during treatment, peripheral blood from 164 patients with breast disease was collected. The prognostic value of CTCs at different measurement time points was demonstrated during breast cancer treatment. The number of CTCs detected by CellSearch system over 1/7.5 ml blood was confirmed to be prognostic for progression-free survival (PFS) and overall survival (OS) in patients with non-metastatic breast c ancer[14]. One study showed that PFS and OS were significantly associated with the number of CTCs after adjuvant chemotherapy but not at 1-week post-surgery[18], indicating that the measurement time point could affect the prognostic value of CTCs. it is necessary to study the prognostic value of the timing of CTC detection during the treatment of Scientific Reports | (2021) 11:13441. Some studies have compared the prognostic relevance of CTCs in breast cancer before and after t reatment[8,19,20], few studies have included different treatment stages
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
